CLINICAL TRIALS

INS-212 CONVERT™ Study Now Recruiting Patients

Insmed is conducting the INS-212 CONVERT Study, a global randomized, phase III, open-label study in adult patients with Nontuberculous Mycobacterial (NTM) lung infection caused by Mycobacterium avium complex (MAC) that is refractory to treatment.